glp-1 malnutrition Impact of GLP- 1 Receptor Agonist Therapy in Patients High Risk for Sarcopenia | Current Nutrition Reports Research has associated GLP-1 medications

Generative AI statement The author(s) declare that no Generative AI was used in the creation of this manuscript

During the 139 weeks of treatment between the baseline and final DXA assessments, BM decreased by 13.2% to 92.8 kg, BMI to 28.5 kg m 2 , and BF% to 21.5%

The overall disease burden decreases even though the fundamental autoimmune process persists

Mounjaros most common side effects include nausea, diarrhoea, and bloating, which can overlap with symptoms from gallbladder removal

they may become an important component of integrated cardiovascular risk reduction strategies in people living with overweight or obesity. GLP-1 medications were originally developed to help manage type 2 diabetes

Increased Helicobacter pylori -associated gastric cancer risk in the Andean region of Colombia is mediated by spermine oxidase